A new dry powder inhalant from Novartis, TOBI Podhaler, has been approved for CF patients with Pseudomonas aeruginosa (Pa) bacteria in the lungs. The drug is the first and only dry powder treatment on the market and reduces treatment time by 70%.
The company has filed suits with the International Trade Commission and US federal court alleging that Taiwan-based APEX Medical Corp and its US distributor Medical Depot, Inc are infringing on multiple ResMed patents for its masks and devices.
PneumRx's LVRC device has been used to treat severe emphysema in US patients as part of an FDA-approved RENEW Study. The implantable device is intended to improve lung function by achieving a lung volume reduction using minimally invasive means.
Contact us about this feature or to become an expert.
RT: For Decision Makers in Respiratory Care (RT) is a leading source of information for respiratory care practitioners. It provides clinical information, updates on trends, practical insights, business tips, and news on the latest product and services. RT covers clinical and current health care issues via in-depth facility profiles, case reports, and feature-length articles that address how health care issues ultimately will affect the respiratory care field.